» Articles » PMID: 22566819

IL-10 Immunomodulation of Myeloid Cells Regulates a Murine Model of Ovarian Cancer

Overview
Journal Front Immunol
Date 2012 May 9
PMID 22566819
Citations 75
Authors
Affiliations
Soon will be listed here.
Abstract

Elevated levels of IL-10 in the microenvironment of human ovarian cancer and murine models of ovarian cancer are well established and correlate with poor clinical prognosis. However, amongst a myriad of immunosuppressive factors, the actual contribution of IL-10 to the ovarian tumor microenvironment, the mechanisms by which it acts, and its possible functional redundancy are unknown. We previously demonstrated that elimination of the myeloid-derived suppressor cell (MDSC) compartment within the ovarian tumor ascites inhibited tumor progression and, intriguingly, significantly decreased local IL-10 levels. Here we identify a novel pathway in which the tumor-infiltrating MDSC are the predominant producers of IL-10 and, importantly, require it to develop their immunosuppressive function in vivo. Importantly, we demonstrate that the role of IL-10 is critical, and not redundant with other immunosuppressive molecules, to in vivo tumor progression: blockade of the IL-10 signaling network results in alleviation of MDSC-mediated immunosuppression, altered T cell phenotype and activity, and improved survival. These studies define IL-10 as a fundamental modulator of both MDSC and T cells within the ovarian tumor microenvironment. Importantly, IL-10 signaling is shown to be necessary to the development and maintenance of a permissive tumor microenvironment and represents a viable target for anti-tumor strategies.

Citing Articles

Myeloid cells: key players in tumor microenvironments.

Hua Q, Li Z, Weng Y, Wu Y, Zheng L Front Med. 2025; .

PMID: 40048137 DOI: 10.1007/s11684-025-1124-8.


Mediating role of circulating inflammatory proteins in the effect of immune cells on esophageal cancer risk: A Mendelian randomization study.

Guo J, Si G, Song X, Si F Medicine (Baltimore). 2024; 103(44):e40374.

PMID: 39496002 PMC: 11537666. DOI: 10.1097/MD.0000000000040374.


Egfl6 promotes ovarian cancer progression by enhancing the immunosuppressive functions of tumor-associated myeloid cells.

Hamze Sinno S, Imperatore J, Bai S, Gomes-Jourdan N, Mafarachisi N, Coronnello C J Clin Invest. 2024; 134(21).

PMID: 39312740 PMC: 11527450. DOI: 10.1172/JCI175147.


Targeting tumor microenvironment for non-small cell lung cancer immunotherapy.

Wang L, Jia Q, Chu Q, Zhu B Chin Med J Pulm Crit Care Med. 2024; 1(1):18-29.

PMID: 39170874 PMC: 11332857. DOI: 10.1016/j.pccm.2022.11.001.


Local administration of myeloid-derived suppressor cells prevents progression of immune-mediated dry eye disease.

Surico P, Lee S, Singh R, Naderi A, Bhullar S, Blanco T Exp Eye Res. 2024; 242:109871.

PMID: 38527580 PMC: 11055659. DOI: 10.1016/j.exer.2024.109871.


References
1.
Klebanoff C, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones A, Finkelstein S . Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A. 2005; 102(27):9571-6. PMC: 1172264. DOI: 10.1073/pnas.0503726102. View

2.
Giuntoli 2nd R, Webb T, Zoso A, Rogers O, Diaz-Montes T, Bristow R . Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res. 2009; 29(8):2875-84. View

3.
Conejo-Garcia J, Benencia F, Courreges M, Kang E, Mohamed-Hadley A, Buckanovich R . Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med. 2004; 10(9):950-8. DOI: 10.1038/nm1097. View

4.
Fontenot J, Gavin M, Rudensky A . Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003; 4(4):330-6. DOI: 10.1038/ni904. View

5.
Ochoa A, Zea A, Hernandez C, Rodriguez P . Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res. 2007; 13(2 Pt 2):721s-726s. DOI: 10.1158/1078-0432.CCR-06-2197. View